|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Hepatitis B
Hepatitis B is a liver disease that makes your liver swell and stops it from working right. It is caused by a virus and spreads by contact with an infected person's blood, semen, or other body fluid. [Source: http://digestive.niddk.nih.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Hepatitis B Study CLDT600AUS06
The purpose of this clinical research study is to determine additional safety and dosing information for the study drug telbivudine for chronic hepatitis B participants who are of Black/Caribbean/African American or Hispanic/Latino ethnicity and between the ages of 16 and 70 years old. Telbivudine has been approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 4 Participation Duration: The participant will be required to take 1 tablet once daily for 52 weeks and visit the doctor’s office 12 times, with an additional 4 follow-up visits at the end of the study. Protocol Number: CLDT600AUS06 |